New late-breaking data presented on Day 3 of EuroPCR 2026 highlighted evolving approaches to antiplatelet therapy, transcatheter treatment of pure aortic regurgitation and procedural optimization in bicuspid TAVR

The Evolut Low Risk trial (Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement; ClinicalTrials.gov identifier: NCT02701283) provides reassuring evidence that transcatheter aortic valve replacement (TAVR) ...

The EuroPCR 2024 meeting, the leading global conference in interventional cardiovascular medicine, was a hub of innovation and cutting-edge research. This year’s event in Paris brought together the world's foremost experts, researchers and clinicians to share the latest advancements and breakthroughs in the field. From novel therapeutic approaches to landmark clinical trials, EuroPCR 2024 provided a comprehensive overview of the current and future landscape of cardiovascular care. We selected our top three trials from this year’s late-breaking sessions:

The global prevalence of aortic stenosis (AS) has steadily increased over the past several decades.1 In high-income countries, degenerative calcific aortic valve disease is the primary aetiology for AS, whereas chronic rheumatic valve disease and infective endocarditis remain more common ...

Aortic stenosis is a common degenerative valve disease and its prevalence increases with age.1 If untreated, severe symptomatic aortic stenosis leads to significant morbidity and mortality.2 Although surgical aortic valve replacement (SAVR) is a well-established treatment option for this condition, ...

Introduction: Aortic valve replacement (AVR) improves outcome in patients with severe aortic stenosis (AS). Nevertheless, late mortality remains high (15–35% at 3.5 years in some series) following AVR and is associated with myocardial scarring. Whether excessive mortality is due to heart failure ...

Introduction: Surgical aortic valve replacement (SAVR) improves outcome in patients with severe aortic stenosis (AS). Nevertheless, late mortality remains high (between 15-35% at 3.5 years in some series) following SAVR. Whether this is related to heart failure or brady-/tachyarrhythmia is ...